A Dangerous and Unrecognized Interaction of Apixaban
Open Access
- 18 November 2021
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 13 (11)
Abstract
Direct oral anticoagulants (DOACs) drug-to-drug interactions are underrecognized by clinicians. Apixaban has cytochrome 450 (CYP) mediated metabolism (primarily by CYP3A4). Strong inducers and inhibitors of this enzyme may cause variations in the blood level of apixaban. This report presents a patient who received a femoral artery stent and developed a large retroperitoneal hemorrhage after she was prescribed apixaban in addition to her antiretroviral therapy (AVT) regimen that included cobicistat, a strong CYP3A4 inhibitor. The patient was managed conservatively, and a repeat computed tomography scan in a subsequent admission revealed near resolution of the hematoma. The treating physicians realized that apixaban should not be prescribed with a potent CYP3A4 inhibitor like cobicistat and discontinued it.Keywords
This publication has 5 references indexed in Scilit:
- Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic reviewThrombosis Research, 2020
- Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug–drug interactions with different perpetrator drugsBritish Journal of Clinical Pharmacology, 2020
- Ritonavir- or cobicistat-boosted antiretroviral therapy and direct oral anticoagulants: A case for apixabanInternational Journal of STD & AIDS, 2019
- Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactionsHematology-American Society Hematology Education Program, 2018
- CT evaluation of retroperitoneal hemorrhage associated with femoral arteriographyAmerican Journal of Roentgenology, 1986